Why the study?
The impact of prediabetes identified by different glycemic thresholds (ADA vs WHO/IEC criteria) and diagnostic tests (FPG vs HbA1c) on clinical outcomes in patients with stable CAD was unclear.
Does prediabetes defined by WHO/IEC criteria versus ADA criteria predict major adverse cardiovascular events in patients with stable coronary artery disease?
Does prediabetes defined by WHO/IEC criteria versus ADA criteria predict major adverse cardiovascular events in patients with stable coronary artery disease?
In patients with stable coronary artery disease, WHO/IEC criteria for prediabetes (driven by HbA1c) better predict major adverse cardiovascular events than ADA criteria.
Answers are grounded in this paper and cite their sources.
WHO/IEC-defined prediabetes was associated with higher MACE risk in stable CAD; leaves open whether stricter thresholds warrant clinical adoption pending trials.
AIMS: To evaluate the impact of prediabetes identified by different glycemic thresholds (according to ADA or WHO/IEC criteria) and diagnostic tests (fasting plasma glucose [FPG] or hemoglobin A1c [HbA1c]) on clinical outcomes in patients with stable coronary artery disease (CAD). METHODS AND RESULTS: In this prospective cohort study, we consecutively enrolled 4088 stable CAD non-diabetic patients with a median follow-up period of 3.2 years. Prediabetes was defined according to ADA criteria as FPG 5.6∼6.9 mmol/L and/or HbA1c 5.7∼6.4%, and WHO/IEC criteria as FPG 6.1∼6.9 mmol/L and/or HbA1c 6.0∼6.4%. The primary endpoint was major adverse cardiovascular event (MACE), including all-cause death, myocardial infarction, or stroke. The prevalence of prediabetes defined according to ADA criteria (67%) was double that of WHO/IEC criteria (34%). Compared with patients with normoglycaemia, those with WHO/IEC-defined prediabetes were significantly associated with higher risk of MACE [adjusted hazard ratio (HR) 1.50, 95% confidence interval (CI) 1.10-2.06], mainly driven by the higher incidence of events in individuals with HbA1c-defined prediabetes. However, this difference was not found in patients with ADA-defined prediabetes and normoglycaemia (adjusted HR 1.17, 95% CI 0.81-1.68). Although FPG was not associated with cardiovascular events, HbA1c improved the risk prediction for MACE in a model of traditional risk factors. Furthermore, the optimal cutoff value of HbA1c for predicting MACE was 5.85%, which was close to the threshold recommended by IEC. CONCLUSION: This study supports the use of WHO/IEC criteria for the identification of prediabetes in stable CAD patients. Haemoglobin A1c, rather than FPG, should be considered as a useful marker for risk stratification in this population. REGISTRATION: Not applicable.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: